AZD1222 US Phase III primary analysis confirms safety and efficacy
76% vaccine efficacy against symptomatic COVID-19 100% efficacy against severe or critical disease and hospitalisation 85% efficacy against symptomatic COVID-19 in participants aged 65 years and overPositive high-level results from the primary analysis of the Phase III trial of AZD1222 in the US have confirmed vaccine efficacy consistent with the pre-specified interim analysis announced on Monday 22 March 2021. These results have been presented to the independent Data Safety Monitoring Board. The primary analysis is pre-specified in the protocol and will be the basis for a